• vcard
  • Education
    • J.D., high honors, Order of the Coif, Chicago-Kent College of Law, 2006, Editor-in-Chief for Chicago-Kent Law Review
    • B.A., Dordt College, 2002, Chemistry
  • Bar Jurisdictions
    • Illinois, 2006
    • Admitted to practice before the United States Patent and Trademark Office, 2007
  • Court Admissions
    • U.S. District Court, Northern District of Illinois, 2007
    • U.S. Court of Appeals, Federal Circuit, 2012
    • State of Illinois, 2006
Luke Shannon believes that there is no “secret formula” for success; rather, success requires careful attention, informed analysis, and sensitivity to each client’s particular needs. He believes that each individual case presents unique strengths that can be leveraged against potential weaknesses. Luke’s industry experience and decade-plus of litigation practice allows him to identify and develop strengths and hedge against weaknesses in order to provide success to the client in the most cost-effective manner. His practice focuses on patent infringement suits arising under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. 

By taking a goal-oriented, big-picture approach, Luke thrives on advancing the client’s case through all stages of litigation, from pre-suit through appeal, to achieve the results that best align with the client’s business goals. He also advises clients regarding post-grant procedures, including inter partes review proceedings, and has experience preparing Paragraph IV notice letters, as well as non-infringement and invalidity opinions. Luke also assists clients in developing design-around product specifications and methods of manufacture. 

Luke’s recent relevant experience includes working with:
  • Small molecules 
  • Compositions and formulations 
  • Polymorphisms 
  • Combinatorial chemistry 
  • Methods of treatment 
  • Pharmaceutical salt forms 

Luke also has experience in preparing patent applications, patentability reports, and freedom to operate opinions in the fields of pharmaceutical compositions, aerosol propellants, consumer products, and sustainable power generation. Prior to entering private practice, Luke served as Judicial Clerk for the Honorable Martin C. Ashman, United States District Court for the Northern District of Illinois. Prior to practicing law, Luke worked as a chemist for a specialty biopharmaceutical company, where he analyzed the purity and efficacy of pharmaceutical products.
  • Represented numerous generic pharmaceutical companies in order to achieve early, pre-suit settlement consistent with the clients’ objectives.
  • Represented generic pharmaceutical company in action related to application for topical ophthalmic solution. After securing invalidity ruling on appeal, we successfully moved to dismiss second-wave litigation involving related patents, because the Court agreed that collateral estoppel prohibited suit. The Federal Circuit affirmed this dismissal.
  • Represented generic pharmaceutical company seeking approval of protease inhibitor drug. After securing admissions during fact and expert discovery, we survived the patent holder’s motion for summary judgment and ultimately achieved settlement of the case.
Related News